CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.

ABSTRACT:

Background

Bone is the predominant site of metastasis from breast cancer, and recent trials have demonstrated that adjuvant bisphosphonate therapy can reduce bone metastasis development and improve survival. There is an unmet need for prognostic and predictive biomarkers so that therapy can be appropriately targeted.

Methods

Potential biomarkers for bone metastasis were identified using proteomic comparison of bone-metastatic, lung-metastatic, and nonmetastatic variants of human breast cancer MDA-MB-231 cells. Clinical validation was performed using immunohistochemical staining of tumor tissue microarrays from patients in a large randomized trial of adjuvant zoledronic acid (zoledronate) (AZURE-ISRCTN79831382). We used Cox proportional hazards regression, the Kaplan-Meier es

SUBMITTER: Westbrook JA 

PROVIDER: S-EPMC4808632 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature